Today’s Ownership Action: Here is What Institutional Investors Think About Merck Sharp & Dohme Corp (NYSE:MRK)

November 24, 2016 - By Vivian Park   ·   0 Comments

Today's Ownership Action: Here is What Institutional Investors Think About Merck Sharp & Dohme Corp (NYSE:MRK)

Sentiment for Merck Sharp & Dohme Corp (NYSE:MRK)

Merck Sharp & Dohme Corp (NYSE:MRK) institutional sentiment decreased to 1.05 in 2016 Q2. Its down -0.02, from 1.07 in 2016Q1. The ratio fall, as 679 active investment managers opened new or increased stock positions, while 634 decreased and sold positions in Merck Sharp & Dohme Corp. The active investment managers in our partner’s database now possess: 1.97 billion shares, down from 1.98 billion shares in 2016Q1. Also, the number of active investment managers holding Merck Sharp & Dohme Corp in their top 10 stock positions increased from 79 to 103 for an increase of 24. Sold All: 51 Reduced: 583 Increased: 583 New Position: 96.

Merck & Co., Inc. is a global healthcare company. The company has a market cap of $168.15 billion. The Firm offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. It has a 31.36 P/E ratio. It operates through one segment, Pharmaceutical.

The stock decreased 0.10% or $0.06 on November 23, hitting $61.64. About 10.24 million shares traded hands. Merck & Co., Inc. (NYSE:MRK) has risen 8.64% since April 22, 2016 and is uptrending. It has outperformed by 3.23% the S&P500.

Analysts await Merck & Co., Inc. (NYSE:MRK) to report earnings on February, 2 before the open. They expect $0.90 EPS, down 3.23% or $0.03 from last year’s $0.93 per share. MRK’s profit will be $2.46 billion for 17.12 P/E if the $0.90 EPS becomes a reality. After $1.07 actual EPS reported by Merck & Co., Inc. for the previous quarter, Wall Street now forecasts -15.89% negative EPS growth.

According to Zacks Investment Research, “Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The company devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate Merck medicines but help deliver them to the people who need them. Merck also publishes unbiased health information as a not-for-profit service.”

Srb Corp holds 11.84% of its portfolio in Merck & Co., Inc. for 1.34 million shares. Foundation Resource Management Inc owns 657,137 shares or 7.05% of their US portfolio. Moreover, Alpine Investment Management Llc has 6.72% invested in the company for 1.52 million shares. The United Kingdom-based Independent Franchise Partners Llp has invested 6.24% in the stock. Healthinvest Partners Ab, a Sweden-based fund reported 224,100 shares.#img1#

Merck & Co., Inc. (NYSE:MRK) Ratings Coverage

Ratings analysis reveals 67% of Merck & Co. Inc.’s analysts are positive. Out of 12 Wall Street analysts rating Merck & Co. Inc., 8 give it “Buy”, 0 “Sell” rating, while 4 recommend “Hold”. The lowest target is $50 while the high is $72. The stock’s average target of $62.22 is 0.94% above today’s ($61.64) share price. MRK was included in 29 notes of analysts from August 13, 2015. On Thursday, July 14 the stock rating was maintained by Jefferies with “Hold”. The rating was maintained by UBS with “Buy” on Friday, August 19. Berenberg initiated the stock with “Buy” rating in Tuesday, November 24 report. The firm has “Hold” rating by Jefferies given on Tuesday, June 14. Barclays Capital maintained the stock with “Overweight” rating in Friday, September 9 report. The stock has “Hold” rating given by Jefferies on Thursday, August 27. Jefferies maintained the shares of MRK in a report on Tuesday, March 15 with “Hold” rating. The stock of Merck & Co., Inc. (NYSE:MRK) has “Outperform” rating given on Tuesday, August 18 by BNP Paribas. Argus Research maintained the stock with “Buy” rating in Tuesday, November 17 report. JP Morgan maintained the stock with “Overweight” rating in Monday, September 21 report.

MRK Company Profile

Merck & Co., Inc., incorporated on 1970, is a global healthcare company. The Firm offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. It operates through one segment, Pharmaceutical. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. The Firm has activities in Pharmaceutical, Animal Health, Alliances and Healthcare Services divisions. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Firm sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers, such as health maintenance organizations, pharmacy benefit managers and other institutions. Vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices.

More news for Merck & Co., Inc. (NYSE:MRK) were recently published by: Fool.com, which released: “Better Buy: Merck & Co. Inc. vs. AbbVie Inc.” on October 25, 2016. Nasdaq.com‘s article titled: “Merck & Co Inc (MRK) Chairman, President & CEO Kenneth C Frazier Sold $9. …” and published on November 11, 2016 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Vivian Park


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>